GRAYMEDY

SOURCE NOTEBOOK / EDITORIAL & IMAGE CREDITS

Evidence cutoff: 31 October 2026. Sources distinguish peer-reviewed research, institutional summaries, company

announcements and preclinical work. Publication dates and study periods are listed separately where relevant.

[1] Sullivan et al. START-001. Nature Medicine, 23 Oct 2026.

[12] UCL via EurekAlert. New trial aims to extend immune system

Published trial abstract.

Read source

lifespan, 17 Jun 2026. Trial plans.

Read source

[2] NIH. Precision T-cell therapy in resistant cancers, 23 Oct 2026.

[13] Lanna et al. Sestrin-MAPK disruptors. bioRxiv, 21 May 2024.

Institutional account.

Read source

Preprint; not peer reviewed.

Read source

[3] NCI. Immunotherapy to Treat Cancer. Background.

Read source

[14] Graymedy. Dr. Harold Varmus profile, 29 Oct 2026.

Read source

[4] NCI. Immunotherapy Side Effects. Background.

Read source

[15] Nobel Assembly. Medicine prize press release, 1989.

Read

source

[5] NCI. How Do Clinical Trials Work? Trial-phase context.

Read

source

[16] NIH. Harold E. Varmus: historical biography.

Read source

[6] argenx. FB102 phase 2 topline results, 8 Oct 2026. Sponsor

[17] NLM. Harold Varmus papers: biographical history.

Read source

announcement; full data pending.

Read source

[18] Graymedy. SIGNA Bolt product spotlight, 21 Oct 2026.

Read

[7] NIDDK. Treatment for Celiac Disease. Current-care background.

source

Read source

[19] GE HealthCare. Clearance announcement, 19 Feb 2026.

Read

[8] NHS. Coeliac disease: treatment. Current-care background.

Read

source

source

[20] GE HealthCare. SIGNA Bolt product specifications.

Read source

[9] Academy of Nutrition and Dietetics guideline, 2023. PubMed

[21] NIBIB. Magnetic Resonance Imaging: education.

Read source

abstract.

Read source

[10] King's College London. Mapping human immune ageing, 13 Oct

2026. Institutional summary of Immunity research.

Read source

[11] UCL. Immune rejuvenation industry collaboration, 8 Oct 2026.

Development announcement.

Read source

PHOTOGRAPHY & PERMISSIONS

Page 01 / NCI /

Photo ct10qdGv1hQ

Page 08 / Matthew Septimus /

NCI via Wikimedia Commons

, 2009.

Public-domain photograph; published Graymedy graphic.

Page 02 / NCI /

Photo rHfsPolwIgk

Page 04 / Mae Mu /

Photo Emhz3miT6mo

Page 05 / NCI /

Photo MOj06jBit0s

Page 09 / GE HealthCare /

RSNA press kit

. Official product image supplied

Page 06 / Mobio Marketing /

Photo l-6xpNpiVIc

for editorial coverage; retained Graymedy copy.

Page 07 / NCI /

Photo rAJHnQz5jHc

Pages 01-07, six distinct photographs:

Unsplash License

; free editorial and commercial reuse, including cropping. Source files retained at 3200 px width. Those

context images do not depict the trials, products, investigators or patients discussed. NCI = National Cancer Institute. No endorsement implied.

UNDERSTANDING THE EVIDENCE

Early clinical activity supports further testing. A statistically significant result does not describe the size of a benefit. An observational association does not

establish causation. Regulatory clearance and comparative clinical superiority are different determinations.

Publication date: Sunday, 1 November 2026. Health information is general; individual treatment decisions require clinical assessment.

10

HEALTH SCIENCE, CLEARLY